Rani Therapeutics (RANI) Stock Performance – 22 October 2026
- Closing price (09:07 PM Central Europe, 22 Oct 2026): USD 0.58
- Percentage change (24 h): ‑7.35 %
- Shares outstanding: 140 million
- Market capitalization: USD 91 million
- 24‑hour trading volume: USD 416 300
- Month‑end change: ‑22.24 %
- 200‑day simple moving average: USD 0.96
- 52‑week high: USD 2.63 (11 Jun 2025)
- 52‑week low: USD 0.60 (21 Oct 2026)
Recent Trading Activity of Related Stocks
| Ticker | 24‑h change | Current price | Market cap (USD m) | Notable event |
|---|---|---|---|---|
| LFMD | ‑4.89 % | USD 2.15 | 108.2 | Announces third‑quarter 2026 results on 9 Nov; conference call at 08:30 ET |
| MRLN | ‑6.67 % | USD 0.85 | 106.1 | — |
| CODA | +2.33 % | USD 9.14 | 109.2 | P/E ratio 21.83 |
| PBHC | ‑2.78 % | USD 16.76 | 108.2 | P/E ratio 631.5 |
| TVGN | ‑5.57 % | USD 6.86 | 107.3 | — |
Company Profile – Rani Therapeutics Holdings, Inc.
- Industry: Healthcare
- Headquarters: San Jose, United States
- Business model: Holding company that develops orally administered biologics through its subsidiaries
- Customer base: United States (in‑house and online)
- Website: www.ranitherapeutics.com
- Exchange listing: Nasdaq
The stock’s recent decline reflects broader market volatility and investor reassessment of the company’s valuation relative to its 200‑day moving average and 52‑week price range.
